Thus, for the WHO 1973 histopathological grading of bladder cancers, we suggest a molecular reclassification of the G2 NMIBCs as follows: we propose to classify Chr17 polysomic and/or HER2 amplified G2 tumors as high-grade (HG) and non-polysomic G2 tumors as low-grade (LG) NMIBCs (G1 and G3 tumors remain graded as low- and high-grade, respectively). This evidence concerns the gene ERBB2 and urinary bladder cancer.